Andrew Cheng - 10 Jan 2022 Form 4/A - Amendment Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President & CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 10 Jan 2022
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 02 Mar 2022, 20:42:05 UTC
Date Of Original Report: 11 Jan 2022
Previous filing: 04 Jan 2022
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AKRO	Common Stock						308,996	10 Jan 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

This amendment is being filed to correct Andrew Cheng's aggregate beneficial holdings, which inadvertently excluded 10,000 shares of common stock held by Andrew Cheng prior to the exercise of his options in the reported transaction.